Effect of Dietary Supplementation on Metabolic Dysfunction-associated Steatotic Liver Disease

INTERVENTION: This is a two‐arm, randomized, double‐blind, controlled clinical trial. A total of 26 participants who meet the eligibility criteria will be randomly allocated in a 1:1 ratio to one of two study groups. Both the outcome assessors and the participants will be blinded to group allocation. Experimental group: thirteen participants with Metabolic dysfunction‐associated steatotic liver disease will receive one oral capsule containing 10 mg of Watacap‐pep19 once daily for 90 days. Control group: thirteen participants with Metabolic dysfunction‐associated steatotic liver disease will receive one oral placebo capsule once daily for 90 days. CONDITION: E88.9 Fatty liver not elsewhere classified ; Metabolic disorder, unspecified PRIMARY OUTCOME: To evaluate the change in hepatic fat fraction using proton density fat fraction in Magnetic resonance imaging SECONDARY OUTCOME: To analyze variations in serum liver enzyme levels, estimated insulin resistance and lipid profile To evaluate changes in body weight, body mass inde Xand body composition INCLUSION CRITERIA: Patients diagnosed with Metabolic Dysfunction‐associated Steatotic Liver Disease; without cirrhosis; body mass inde Xof 25 kg/m² or greater; of either gender; aged 18 years or older